Rabeprazole: Second-generation proton pump inhibitor
Rabeprazole (brand name Pariet, many generics) belongs to the proton pump inhibitor (PPI) class and reliably and durably suppresses gastric acid production. The compound was first approved in Japan in 1998, followed by EU and US launches. Like all PPIs, rabeprazole binds covalently to the H+/K+ ATPase (the proton pump) of parietal cells in the stomach, halting the final step of acid secretion.
In daily practice, rabeprazole is used in gastroesophageal reflux disease, peptic ulcers and as part of Helicobacter pylori eradication regimens. Compared with omeprazole, rabeprazole shows somewhat faster activation in acidic conditions and a lower dependence on CYP2C19, which can offer advantages for patients with reduced enzyme activity.
Mechanism of action
Rabeprazole is a substituted benzimidazole that circulates in plasma as an inactive, neutral prodrug. Only in the highly acidic secretory canaliculi of the parietal cell (pH below 1.5) does it become protonated and rearrange into the active sulphenamide. This active species binds covalently to cysteine residues of the alpha subunit of the H+/K+ ATPase, the final pump of acid secretion.
Because the binding is covalent and irreversible, acid suppression lasts much longer than the plasma half-life of about one hour would suggest. Acid production resumes only when newly synthesised proton pumps appear, which explains the duration of action of 24 hours or more. After discontinuation, acid secretion recovers over two to three days.
A specific feature of rabeprazole is partial non-enzymatic reduction to thioether metabolites. Activation is therefore less dependent on CYP2C19 than for omeprazole, which can be clinically relevant when co-prescribed with clopidogrel.
Indications
- Gastroesophageal reflux disease (GERD): erosive and non-erosive reflux esophagitis, symptom control of heartburn and acid regurgitation, long-term relapse prophylaxis
- Duodenal and gastric ulcer: acute therapy and relapse prophylaxis
- Helicobacter pylori eradication: as part of French or Italian triple therapy and bismuth-based quadruple therapy
- Zollinger Ellison syndrome: high-dose treatment to suppress pathological acid secretion
- NSAID gastropathy prophylaxis: in at-risk patients on chronic analgesics, as an alternative to other PPIs
Rabeprazole is mainly available in Germany as 10 mg and 20 mg gastro-resistant tablets. In the US, a sprinkle formulation for children is also available.
Dosing and administration
Reflux esophagitis: 20 mg once daily for 4 to 8 weeks. Maintenance: 10 or 20 mg daily. Symptomatic GERD without endoscopy: 10 mg daily on demand.
Duodenal ulcer: 20 mg daily for 4 weeks. Gastric ulcer: 20 mg daily for 6 to 8 weeks.
Helicobacter eradication: 20 mg twice daily plus two antibiotics (classically amoxicillin and clarithromycin) for 7 to 14 days.
Zollinger Ellison syndrome: starting at 60 mg daily, individually titrated up to 100 or 120 mg, sometimes split into two doses.
The tablet is taken in the morning before breakfast, since PPIs are most effective on actively secreting proton pumps. Tablets must be swallowed whole, as the gastro-resistant coating protects the active ingredient from gastric acid.
No dose adjustment is needed in renal impairment. In severe hepatic impairment, caution is advised because plasma levels can rise.
Side effects
Common (1 to 10 %): headache, nausea, diarrhea, constipation, abdominal pain, flatulence, sleep disturbance, weakness, cough, pharyngitis. Most settle after the first days of treatment.
Uncommon: dermatitis, pruritus, dizziness, raised liver transaminases, visual disturbance, dry mouth, taste disorders.
Rare and very rare: anaphylaxis, Stevens Johnson syndrome, toxic epidermal necrolysis, acute interstitial nephritis, hepatitis up to liver failure, agranulocytosis, subacute cutaneous lupus erythematosus.
Long-term risks with months or years of therapy:
- Hypomagnesaemia with tetany, seizures or cardiac arrhythmias
- Vitamin B12 deficiency due to reduced intrinsic factor dependent absorption
- Increased fracture risk (hip, vertebra) with prolonged high-dose therapy
- Higher infection rate (Clostridioides difficile, community-acquired pneumonia)
- Iron deficiency and possible impairment of calcium absorption
Patients often ask whether they need to take a PPI for life. The honest answer is that with a clear indication the benefit outweighs the risk, while with an unclear indication a regular taper attempt and stepping down to the lowest effective dose make sense.
Interactions
- Atazanavir, nelfinavir, rilpivirine: reduced absorption due to higher gastric pH; combination should be avoided where possible
- Ketoconazole, itraconazole, posaconazole suspension: reduced bioavailability; use alternative antifungals or tablet formulations
- Methotrexate: increased plasma levels and delayed elimination on high-dose regimens; PPI should be paused
- Digoxin: increased absorption, monitor levels
- Iron supplements, calcium carbonate: reduced absorption; citrate or gluconate salts are preferred
- Clopidogrel: rabeprazole inhibits CYP2C19 less than omeprazole or esomeprazole and is therefore the preferred option if PPI therapy is unavoidable
- Warfarin: isolated INR rises have been reported, monitoring recommended
Special considerations
Pregnancy: data are limited. If a PPI is necessary during pregnancy, omeprazole has the most data. Rabeprazole should only be used when benefit outweighs the potential risk.
Breastfeeding: rabeprazole transfers into milk in animal studies; human data are lacking. Manufacturer information advises against breastfeeding during therapy.
Children: approved from 12 years for reflux esophagitis. Study data exist for younger children, but no German approval.
Masking gastric cancer: alarming symptoms (weight loss, anemia, dysphagia, hematemesis) should be investigated endoscopically before long-term PPI therapy, since PPIs can mask symptoms of gastric cancer.
Discontinuation: after prolonged therapy, an acid rebound hypersecretion can occur and may be misread as worsening disease. Stepwise tapering over two to four weeks makes discontinuation easier.
Related substances
- Omeprazol, the classic among proton pump inhibitors
- Pantoprazol with a particularly favourable interaction profile
- Esomeprazole, the eutomer of omeprazole
- Clopidogrel, whose activation depends on CYP2C19
- Methotrexat, whose levels can rise under PPIs
Frequently asked questions
How does rabeprazole differ from omeprazole?
Rabeprazole is activated somewhat faster in acidic conditions and is less CYP2C19 dependent. Clinically the two PPIs barely differ in acid suppression; in patients on clopidogrel or with a relevant CYP2C19 genotype rabeprazole can be the more robust choice.
Can I just stop rabeprazole when symptoms are gone?
After short courses this is usually unproblematic. After several weeks of high-dose therapy, an acid rebound hypersecretion can occur. We recommend tapering the dose stepwise and switching to on-demand use if needed.
What are the risks of years of PPI therapy?
Observational studies link long-term PPI use to vitamin B12 deficiency, hypomagnesaemia, osteoporosis, kidney problems and a slightly higher infection rate. The individual risk is small, but long-term therapy should always be reviewed regularly.
Is 10 mg enough or do I need 20 mg?
10 mg daily is often enough for non-erosive reflux and maintenance therapy. For erosions, ulcer or eradication therapy 20 mg in the morning (or twice daily for eradication) is standard. The dose is matched to the symptom profile and endoscopic findings.
Sources
- EMA European Medicines Agency
- BfArM Federal Institute for Drugs and Medical Devices
- AWMF guideline GERD and Helicobacter pylori
- Gelbe Liste rabeprazole monograph
Legal notice and disclaimer
The information on this page is provided for general information purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be used after a doctor's prescription or pharmacy supply. All information is based on summaries of product characteristics and accepted scientific sources at the time of writing; the current SmPC of the manufacturer is always decisive. Sanoliste accepts no liability for completeness, timeliness or accuracy. In a medical emergency, dial the emergency number 112.